Search
Rivoceranib
go.drugbank.com/drugs/DB14765InvestigationalRivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
Amisulpride
go.drugbank.com/drugs/DB06288ApprovedInvestigationalAmisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. … [A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders
Synonyms: 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide, 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamideLevonordefrin
go.drugbank.com/drugs/DB06707ApprovedInvestigationalLevonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.
Mixtures: Isocaine HCl Inj 2%, Scandonest LSynonyms: L-Nordefrin, L-alpha-methylnoradrenalineIDD-3
go.drugbank.com/drugs/DB05427ExperimentalIDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. … It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
Carbamoylcholine
go.drugbank.com/drugs/DB00411ApprovedCarbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932. … Carbamoylcholine was granted FDA approval on 28 September 1972.[L30245]
Categories: Compounds used in a research, industrial, or household settingPanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Depemokimab
go.drugbank.com/drugs/DB18846ApprovedInvestigationalDepemokimab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody and a long-acting drug. … [A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence.
Elvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalElvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. … Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.
Categories: Antivirals used in combination for the treatment of HIV infectionsPibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalThese resistance-associated amino acid substitutions included Q30D/deletion, Y93D/H/N or H58D +Y93H in genotype 1a replicons, F28S + M31I or P29S + K30G in genotype 2a replicons, and Y93H in genotype 3a … Individual NS5A amino acid substitutions that reduced susceptibility to pibrentasvir include M28G or Q30D in a genotype 1a replicon and P32-deletion in a genotype 1b replicon [L940].
Upadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalUpadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. … Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints.